title: [Is rituximab a promising treatment for Sjögren's syndrome?].
authors.forename: V
authors.initials: V
authors.lastname: Devauchelle-Pensec
authors.forename: J O
authors.initials: JO
authors.lastname: Pers
authors.forename: P
authors.initials: P
authors.lastname: Youinou
authors.forename: A
authors.initials: A
authors.lastname: Saraux
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001323:Autoantibodies; D001402:B-Lymphocytes / Q000187:drug effects; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005602:France; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D051379:Mice; D015337:Multicenter Studies as Topic; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D001323:Autoantibodies; D005938:Glucocorticoids; D000069283:Rituximab; D011239:Prednisolone; D008775:Methylprednisolone